Liquidia Corp
A biopharmaceutical company that makes YUTREPIA, an inhaled powder that treats pulmonary arterial hypertension, a rare disease of high blood pressure in the lungs. It grew out of work by chemist Joseph DeSimone at the University of North Carolina, who invented a PRINT technology that molds drug particles into precise sizes and shapes, an idea borrowed from how semiconductors are made. The company, based in Morrisville, North Carolina, still builds on that particle-molding method today.
Granted 1.17M · Bought 1.27M · Sold 155.3K
Granted 24.3K · Sold 1.38M
Granted 44.6K · Bought 616.4K · Sold 870.8K
Granted 776.0K · Bought 139.7K · Sold 780.3K
Granted 337.3K · Sold 110.3K
Granted 676.4K · Sold 507.1K
Granted 3.4K · Sold 1.0K
Granted 319.8K · Sold 245.0K
Granted 64.6K · Sold 53.9K
Granted 307.0K · Sold 192.2K
Granted 215.4K · Sold 226.5K
Granted 64.6K · Sold 64.2K
Granted 44.6K
Granted 34.3K · Sold 4.1K
Granted 44.6K · Sold 30.0K
Granted 139.7K · Sold 102.5K
Granted 99.8K · Sold 55.2K
Granted 44.6K · Sold 5.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Caligan Partners LP +1 co-filerDirector, 10% owner, See Remarks., Director, 10% owner · 10 transactions | — | 16.30M | 1.17M | 1.27M | 155.3K |
| Bloch Stephen MDirector · 37 transactions | — | 6.09M | 24.3K | — | 1.38M |
| Manning Paul BDirector · 16 transactions | — | 5.79M | 44.6K | 616.4K | 870.8K |
| Jeffs RogerChief Executive Officer, Director · 46 transactions | — | 4.57M | 776.0K | 139.7K | 780.3K |
| Schundler RussellGeneral Counsel · 41 transactions | +60.1% | 625.0K | 337.3K | — | 110.3K |
| Kaseta MichaelCFO and COO · 58 transactions | +100.1% | 353.4K | 676.4K | — | 507.1K |
| Lippe Robert AChief Operations Officer · 4 transactions | +1.9% | 193.8Kas of Nov 2023 | 3.4K | — | 1.0K |
| Moomaw ScottChief Commercial Officer · 53 transactions | +79.3% | 184.6K | 319.8K | — | 245.0K |
| Boyle DanaChief Accounting Officer · 17 transactions | — | 175.3K | 64.6K | — | 53.9K |
| Adair JasonChief Business Officer · 77 transactions | +197.4% | 174.6K | 307.0K | — | 192.2K |
| Saggar RajeevChief Medical Officer · 33 transactions | -2.2% | 173.3K | 215.4K | — | 226.5K |
| Krepp SarahChief Human Resource Officer · 15 transactions | — | 141.0K | 64.6K | — | 64.2K |
| deGoa DamianDirector · 3 transactions | +93.5% | 92.4K | 44.6K | — | — |
| Khindri SanjeevChief Development Officer · 2 transactions | — | 67.1K | 34.3K | — | 4.1K |
| Kirsch Arthur SDirector · 6 transactions | — | 46.6K | 44.6K | — | 30.0K |
| Singh RamanDirector · 12 transactions | — | 44.6K | 139.7K | — | 102.5K |
| Rielly-Gauvin KatherineDirector · 9 transactions | — | 44.6K | 99.8K | — | 55.2K |
| Horobin JoannaDirector · 4 transactions | — | 39.6K | 44.6K | — | 5.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -2.75M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.